Imfinzi Regimen Cuts Early Gastric Cancer Risk by 29% in Phase III Trial
AstraZeneca’s Imfinzi-Based Regimen Shows Significant Benefit in Early Gastric and GEJ Cancers in Phase III MATTERHORN Trial AstraZeneca has reported highly promising results from its Phase III MATTERHORN trial, showcasing…
Roche’s Fenebrutinib Sustains Disease Control in Relapsing MS for Two Years
Roche Reports Promising Two-Year Results for Fenebrutinib in Relapsing Multiple Sclerosis, Maintaining Disease Control and Halting Disability Progression Roche has released encouraging new long-term data from its investigational Bruton’s tyrosine…
Merck’s Zilovertamab Vedotin Shows Promising Results in Phase 2 DLBCL Trial
Merck’s Zilovertamab Vedotin in Combination With R-GemOx Shows Promising Efficacy in Relapsed/Refractory DLBCL Patients: Phase 2 Results from waveLINE-003 Trial Presented at ASCO 2025 Merck, known as MSD outside the…
Merck’s KRAS G12C Inhibitor MK-1084 Shows Antitumor Activity in Early Trial
Merck Reports Encouraging Early Data for Investigational KRAS G12C Inhibitor MK-1084 in Phase 1 Trial for Advanced Colorectal and Lung Cancers Merck known as MSD outside the United States and…
AbbVie and Chicago Cubs Join Forces in the Fight Against Cancer
AbbVie and the Chicago Cubs Launch Multi-Year “Striking Out Cancer” Campaign to Support Cancer Awareness and Research In a bold and heartfelt effort to turn America’s favorite pastime into a…
Teva Launches Acceleration Phase of Growth Strategy at 2025 Innovation Day
Teva Embarks on Acceleration Phase of “Pivot to Growth” Strategy at 2025 Innovation & Strategy Day, Signaling Renewed Focus on Biopharmaceutical Leadership and Long-Term Shareholder Value Teva Pharmaceutical Industries Ltd.one…
China Accepts NDA for Naldemedine to Treat Opioid-Induced Constipation
China Accepts New Drug Application for Shionogi’s Naldemedine to Treat Opioid-Induced Constipation Shionogi & Co., Ltd., a leading Japanese pharmaceutical company headquartered in Osaka, has announced a key regulatory milestone…
Astellas, Evopoint Ink Exclusive Deal for CLDN18.2-Targeting ADC XNW27011
Astellas Secures Global Rights to Evopoint’s Promising CLDN18.2-Targeting Antibody-Drug Conjugate XNW27011 in Strategic Oncology Expansion In a strategic move that reinforces its commitment to precision oncology, Astellas Pharma Inc. has…
Analysts Downplay Intellia Setback, Gene Therapy Safety Still in Focus
Intellia Grapples with Safety Questions in ATTR Gene Editing Trial Amid Broader Sector Scrutiny Intellia Therapeutics’ stock took a steep dive Thursday morning, shedding approximately 26% of its value after…
CVS Health Sues to Shield Arkansans from Impact of Act 624
CVS Health Files Federal Lawsuit to Halt Arkansas’ Act 624, Citing Harm to Patients, Jobs, and Healthcare Access On May 29, 2025, CVS Health® filed a federal lawsuit seeking to…
Beyfortus Gains Edge in First Real-World RSV Immunization Comparison
Beyfortus Shows Stronger Public Health Impact Than Maternal RSV Vaccine in Landmark Real-World Comparison In a pivotal step forward for infant respiratory health, new real-world data from an immunization program…
Member States Back World Prematurity Day as Global Health Campaign
Member States Officially Endorse World Prematurity Day as a Global Health Campaign at the 78th World Health Assembly At the recently concluded 78th World Health Assembly (WHA), a historic and…